ArticleDiscover oncology2025
Causal relationships between immune cell traits and HER2 subtypes in breast cancer: a Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the relationship between uric acid-to-HDL cholesterol ratio and vascular calcification: evidence from clinical, genetic, and network-based analyses.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBreast cancer can be classified based on HER2 status into HER2-positive (HER2+) and HER2-negative (HER2-) subtypes, which differ significantly in pathogenesis, prognosis, and treatment response. Immune cells are critical components of the tumor microenvironment, influencing breast cancer progression. However, their specific roles in HER2 + and HER2- breast cancer subtypes are not yet fully understood.
methodsThis study applied Mendelian randomization (MR) analysis to investigate causal relationships between 731 immune cell phenotypes and breast cancer with different HER2 statuses. Genetic data were obtained from the Finngen and OPENGWAS databases. Inverse variance weighted (IVW) analysis and sensitivity tests were used to ensure the robustness of results.
resultsOur analysis revealed significant associations between specific immune cell traits and breast cancer subtypes. For instance, B cell traits such as "Sw mem %B cell" and "IgD- CD38- %B cell" were positively correlated with the development of HER2 + breast cancer. Conversely, traits associated with T cell maturation and myeloid cells demonstrated a negative correlation with HER2 + breast cancer. Regulatory T cell traits were more strongly linked to HER2- breast cancer.
conclusionsDistinct immune cell profiles are associated with HER2 + and HER2- breast cancers. These findings provide insights into the immunological differences between subtypes and suggest potential targets for personalized immunotherapy strategies. Further research is required to clarify underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.